USAN drug names under consideration

USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.

Visit United States Adopted Names FAQ to learn more.

Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected]. 

In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following names for the drugs described are "under consideration" by the USAN Council:

Baluretgene parvec: Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

Ceperognastat: Treatment of neurodegenerative diseases and disorders, such as Alzheimer's disease (AD)

Clemidsogene lanparvovec: Treatment of Treatment of mucopolysaccharidosis Type II (MPS II)

Firmonertinib: Antineoplastic

Firmonertinib mesylate: Antineoplastic

Laporolimus: Preventing proliferation and migration of smooth muscle cells, to inhibit restenosis after vascular injury

Lixudebart: Treatment of advanced liver fibrosis  

Migaldendranib: Treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME)    

Mosnodenvir: Prevention and treatment of dengue infection  

Nexiguran: Treatment of transthyretin amyloidosis (ATTR) 

Obudanersen: Treatment of Angelman syndrome (AS)

Obudanersen sodium: Treatment of Angelman syndrome (AS)

Opnurasib: Antineoplastic 

Potravitug: Antiviral  

Prifetrastat: Antineoplastic   

Renizgamglogene autogedtemcel: Treatment of severe sickle cell disease (SCD) and transfusion‐dependent beta thalassemia (TDT)    

Rezatapopt: Antineoplastic 

Rugecitide: Treatment of cardiovascular disease (CVD) and related conditions, including heart failure    

Saruparib: Treatment of advanced solid tumors  

Solengepras: Treatment of Parkinson’s disease  

Tobemstomig: Antineoplastic 

Xeruborbactam: Treatment of Gram-negative bacterial infection

Xeruborbactam sodium: Treatment of Gram-negative bacterial infection

Zelenectide: Antineoplastic

Zelenectide pevedotin: Antineoplastic

Zelicapavir: Treatment of respiratory syncytial virus (RSV) infection

Certociclib: Antineoplastic

Claturafenib: Antineoplastic

Clofutriben: Treatment of conditions in which excess cortisol is present

Colulintide: Chronic weight management in adults with obesity

Copper histidinate: Treatment of Menkes disease 

Delocamten: Treatment of Heart Failure 

Duvakitug: Treatment of ulcerative colitis and Crohn’s disease  

Iluzanebart: Treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)  

Indenebart: Treatment of Parkinson’s disease and multiple system atrophy  

Milpecitinib: Control of pruritis associated with canine allergic dermatitis and/or control of canine atopic dermatitis (CAD)

Ompekimig: Treatment of atopic dermatitis and other inflammatory medicated conditions

Rizedisben: Pharmaceutical aid to enhance intraoperative visualization of nerve structures

Rizedisben hydrochloride: Pharmaceutical aid to enhance intraoperative visualization of nerve structures

Sovleplenib: Antineoplastic and treatment of inflammatory diseases or autoimmune diseases

Sovleplenib acetate: Antineoplastic and treatment of inflammatory diseases or autoimmune diseases

Tegtociclib: Antineoplastic

Tilrekimig: Treatment of atopic dermatitis and other immune/inflammatory conditions

Veligrotug: Treatment of thyroid eye disease

Ziclumeran: Treatment of transthyretin amyloidosis (ATTR)

Zolacabtagene autoleucel: Treatment of patients with B-cell malignancies and B-cell mediated autoimmune conditions including Systemic Lupus Erythematosus (SLE)

Benzgalantamine: Treatment of Alzheimer’s disease and memory/cognitive impairment

Benzgalantamine gluconate: Treatment of Alzheimer’s disease and memory/cognitive impairment

Bezisterim: Treatment of systemic and neuroinflammatory disease

Brenetafusp: Antineoplastic

Brogidirsen: Treatment of Duchenne muscular dystrophy 

Cemsidomide: Antineoplastic 

Dibutepinephrine: Emergency treatment of type 1 allergic reactions, including anaphylaxis 

Dibutepinephrine hydrochloride: Emergency treatment of type 1 allergic reactions, including anaphylaxis    

Inaxaplin: Treatment of APOL1-mediated kidney disease (AMKD) in individuals with 2 apolipoprotein L1 (APOL1) mutations  

Midomafetamine hydrochloride: Treatment of post-traumatic stress disorder (PTSD) 

Niraparib tosylate: Treatment of solid tumors

Oditrasertib: Treatment of amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) 

Pimicotinib: Antineoplastic, anti-inflammatory

Pimicotinib hydrochloride: Antineoplastic, anti-inflammatory

Satricabtagene autoleucel: Treatment of advanced solid tumors, including pancreatic and stomach cancer

Utenpanium: Treatment of fat-related disorders such as Dercum’s disease (DD) lipomas and aesthetic conditions such as excessive submental fat or large fat deposits in the flanks 

Utenpanium chloride: Treatment of fat-related disorders such as Dercum’s disease (DD) lipomas and aesthetic conditions such as excessive submental fat or large fat deposits in the flanks

Vamikibart: Treatment of ocular posterior inflammatory diseases

Vidutolimod: Antineoplastic

Vopikitug: Antineoplastic

Zasocitinib: Treatment of plaque psoriasis and psoriatic arthritis